Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath
- 1San Diego Cardiac Center Medical Group, San Diego, California, USA. Electronic address: https://twitter.com/SrivastavaPrat.
Abstract
Immune checkpoint inhibitor (ICI)–associated myocarditis remains one of the most serious immune-related adverse events and can present major challenges after hospital discharge. Although guidelines and expert consensus statements have addressed diagnostic and management strategies in the acute phase, there is a paucity of evidence for post-discharge management and how to address recrudescence of symptoms and/or biomarkers suggesting rebound myocarditis. This review synthesizes evidence on the pathophysiology of ICI myocarditis, including the T cell–macrophage inflammatory loop that sustains smoldering disease, and provides a framework for outpatient management. We address steroid tapering strategies, the taper-flare phenomenon, and evidence for second-line agents and emerging therapies. Practical guidance is provided for biomarker surveillance, cardiac imaging protocols, antimicrobial prophylaxis, and the balance between immunosuppression and infection risk. This review aims to highlight and address significant gaps in cardio-oncology practice by offering clinicians an evidence-informed roadmap for managing this complex patient population.
Related
- Integrated multi-omics identifies distinct immune signatures with diagnostic and therapeutic implications in immune checkpoint inhibitor-induced myocarditis
- Electrophysiologic Phenotype Outperforms Left Ventricular Ejection Fraction for Mortality Prediction in Immune Checkpoint Inhibitor Myocarditis.
- A serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis
- Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis
- 1027 Foundation-model-based CT detection of pneumonitis-compatible abnormalities during immune checkpoint inhibitor surveillance
BibTeX
@article{morad2026management,
title = {{Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath}},
author = {Tyler T Morad and Mohammad Keykhaei and Devon A Terraciano and Pratyaksh K Srivastava and Eric H Yang and Ashley F Stein-Merlob},
journal = {JACC: CardioOncology},
year = {2026},
month = oct,
doi = {10.1016/j.jaccao.2026.09.003},
url = {https://doi.org/10.1016/j.jaccao.2026.09.003},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath
AU - Tyler T Morad
AU - Mohammad Keykhaei
AU - Devon A Terraciano
AU - Pratyaksh K Srivastava
AU - Eric H Yang
AU - Ashley F Stein-Merlob
PY - 2026
DA - 2026/10/01
JO - JACC: CardioOncology
DO - 10.1016/j.jaccao.2026.09.003
UR - https://doi.org/10.1016/j.jaccao.2026.09.003
AB - Immune checkpoint inhibitor (ICI)–associated myocarditis remains one of the most serious immune-related adverse events and can present major challenges after hospital discharge. Although guidelines and expert consensus statements have addressed diagnostic and management strategies in the acute phase, there is a paucity of evidence for post-discharge management and how to address recrudescence of symptoms and/or biomarkers suggesting rebound myocarditis. This review synthesizes evidence on the pathophysiology of ICI myocarditis, including the T cell–macrophage inflammatory loop that sustains smoldering disease, and provides a framework for outpatient management. We address steroid tapering strategies, the taper-flare phenomenon, and evidence for second-line agents and emerging therapies. Practical guidance is provided for biomarker surveillance, cardiac imaging protocols, antimicrobial prophylaxis, and the balance between immunosuppression and infection risk. This review aims to highlight and address significant gaps in cardio-oncology practice by offering clinicians an evidence-informed roadmap for managing this complex patient population.
SN - 2666-0873
ER -